Replicate Bioscience Announces Collaboration with Precision NanoSystems to Deliver Up to 15 New srRNAs

July 26, 2022Client News

Gunderson Dettmer represented client Replicate Bioscience, a San Diego-based biotechnology company, in its licensing agreement to collaborate with Precision NanoSystems, a developer of genetic medicines for infectious diseases, cancer, and rare diseases. The collaboration agreement will enable Replicate and Precision NanoSystems to accelerate the creation, scale-up, and delivery of self-replicating RNA (srRNA) therapies and help support the development of up to 15 new genomic medicine products.

In the announcement of the collaboration, Co-founder and Chief Development Officer of Replicate Andy Geall, Ph.D said, "I'm confident in PNI's delivery technology and our working relationship. With this agreement, Replicate aims to significantly expand our portfolio of srRNA therapeutics beyond our lead candidates slated to enter human trials next year."

The Gunderson Dettmer deal team was led by Brendan McCarthy and included Brittany Nicely.

Replicate Bioscience
Precision NanoSytems